Tafasitamab(Synonyms: XmAb5574; MOR00208; Tafasitamab-cxix)

发表于由

上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白，专注于信号通路和疾病研究领域。

Tafasitamab (Synonyms: XmAb5574; MOR00208; Tafasitamab-cxix)

Tafasitamab 是一种Fc修饰的人源化单克隆抗体，可与人B细胞表面抗原CD19结合。

Tafasitamab(Synonyms: XmAb5574; MOR00208; Tafasitamab-cxix)

Tafasitamab Chemical Structure

CAS No. : 1422527-84-1

规格 是否有货
100 mg   询价  
250 mg   询价  
500 mg   询价  

* Please select Quantity before adding items.

生物活性

Tafasitamab is an Fc-modified, humanized monoclonal antibody that binds to the human B-cell surface antigenCD19[1][2].

体外研究
(In Vitro)

Tafasitamab induces cytotoxicity against Mino and Jeko (MCL) cell lines in an E/T ratio-dependent manner XmAb5574 increases ADCP and antiproliferative activity. Tafasitamab (XmAb5574) enhances antiproliferative apoptotic activity due to caspase-induced apoptosis[1][2].

Shanghai Jinpan Biotech Co Ltd has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Cytotoxicity Assay[1]

Cell Line: NHL cell lines and primary CLL and MCL cells by γδ T cells
Concentration:
Incubation Time: 2 h
Result: Induced killing of NHL cell lines and primary CLL and MCL cells by γδ T cells.

Cell Proliferation Assay[2]

Cell Line: SU-DHL-6 cells
Concentration:
Incubation Time: 72 h
Result: Showed potent antiproliferative effects on tumor cell.

Apoptosis Analysis[2]

Cell Line: SU-DHL-6 cells
Concentration: 0-4 ng/mL
Incubation Time: 48 h
Result: Showed potent antiproliferative effects due to caspase-induced apoptosis

体内研究
(In Vivo)

Tafasitamab (SC, once on Day 1, 2.5 μg/kg) inhibits lymphoma growth in disseminated BL mouse xenograft tumor models[1].

Shanghai Jinpan Biotech Co Ltd has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: Disseminated Raji model[1].
Dosage: 2.5 μg/kg
Administration: Tafasitamab (SC, once on Day 1, 2.5 μg/kg)
Result: Showed antitumor activity in disseminated Raji model.
Animal Model: Disseminated Ramos model[1].
Dosage: 10 mg/kg
Administration: Tafasitamab (IV, on Days 3, 6, 10, 13, 17, and 20 at a dose of 10 mg/kg)
Result: Showed antitumor activity in disseminated Ramos model.

CAS 号

1422527-84-1
运输条件

Room temperature in continental US; may vary elsewhere.
储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.
参考文献

  • [1]. Jung Hyun Her, et al. Tafasitamab mediates killing of B-cell non-Hodgkin’s lymphoma in combination with γδ T cell or allogeneic NK cell therapy. Cancer Immunol Immunother. 2022 Mar 29.

    [2]. Holly M Horton, et al. Potent in vitro and in vivo activity of an Fc-engineered anti-CD19 monoclonal antibody against lymphoma and leukemia. Cancer Res

所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务